For the health of your patients and practice

Treating and Managing Periodontal Disease

Assessing the Periodontal Patient

Calibration of Periodontal Charting

Presented by Catherine Cabanzon, CRDH, BASDH
Watch this presentation to learn about how calibration is a more consistent way to diagnose periodontal disese.

WATCH VIDEO >

Periodontal Disease Risk-based Care

Presented by Catherine Cabanzon, CRDH, BASDH
Watch this presentation to learn how risk assessment can help determine a patient’s likelihood of developing periodontal disease.

WATCH VIDEO >

Clinical Attachment Level Diagnosis

Presented by Catherine Cabanzon, CRDH, BASDH
Watch this presentation to learn why an accurate measurement of clinical attachment loss is important to the identification of periodontal disease.

WATCH VIDEO >

Prioritizing the Periodontal Patient

The Why and How of Patient Communication

Presented by Catherine Cabanzon, CRDH, BASDH Watch this presentation to learn more about how to communicate with your patients.

WATCH VIDEO >

Need Periodontal Patient Communication Help?

Quick Tip Guide for communicating about periodontal disease with patients.

DOWNLOAD PDF

Additional Resources

dental hygenist wearing mask working over a patient in dental chair

Adjunctive Periodontal Therapy

Presented by Dr. Timothy Donley, DDS, MSD
Watch this presentation to learn about incorporating ARESTIN into periodontal treatment planning.

WATCH VIDEO >

light blue circles of various sizes, representing microspheres of ARESTIN, against a dark blue background

How to Administer ARESTIN® (minocycline HCI) Microspheres, 1mg

Watch this animated video to see how to administer ARESTIN.

WATCH VIDEO >

3 dental hygenists tools on a dark blue background

ARESTIN + SRP

Watch this video to learn more about using ARESTIN in combination with SRP.

WATCH VIDEO >

Staging and Grading

Understand how the American Academy of Periodontology staging and grading guidelines can be utilized to evaluate for periodontitis.

DOWNLOAD PDF

Post Procedure Instructions

Provide this resource to patients following treatment with ARESTIN to help them understand the recovery process.

DOWNLOAD PDF

many yellow spheres bursting upwards, representing microspheres of ARESTIN, on a black background many yellow spheres bursting upwards, representing microspheres of ARESTIN, on a black background

Treating Periodontal Disease

See how adding ARESTIN to scaling and root planing (SRP) can help reduce pocket depth and play a role in the management of periodontal disease. Download Spanish PDF

DOWNLOAD PDF

male dentist wearing mask talking to patient in dentist chair male dentist wearing mask talking to patient in dentist chair

Quick Tips for Use of Arestin

This guide illustrates how to administer ARESTIN with step-by-step visuals.

DOWNLOAD PDF

Take the Poll

How often does your office calibrate?




Vote >  View Results
 

Contact Us

Interested in opportunities to become a key opinion leader for OraPharma? Contact us at Education1@OraPharma.com

Interested in speaking with a Representative? Call our Customer Care Center 1-866-273-7846 Monday through Friday, 8:30 am to 5:00 pm ET

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Be sure to check back often for additional education materials that will be added in future site updates

INDICATION

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planning (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.
  • THE USE OF DRUGS OF THE TETRACYCLINE CLASS DURING TOOTH DEVELOPMENT MAY CAUSE PERMANENT DISCOLORATION OF THE TEETH, AND THEREFORE SHOULD NOT BE USED IN CHILDREN OR IN PREGNANT OR NURSING WOMEN.
  • Tetracyclines, including oral minocycline, have been associated with development of autoimmune syndromes including a lupus-like syndrome manifested by arthralgia, myalgia, rash, and swelling. Sporadic cases of serum sickness-like reaction have presented shortly after oral minocycline use, manifested by fever, rash, arthralgia, lymphadenopathy and malaise. In symptomatic patients, diagnostic tests should be performed and ARESTIN treatment discontinued.
  • The use of ARESTIN in an acutely abscessed periodontal pocket or for use in the regeneration of alveolar bone has not been studied.
  • The safety and effectiveness of ARESTIN has not been established in immunocompromised patients or in those with coexistent oral candidiasis. Use with caution if there is a predisposition to oral candidiasis.
  • In clinical trials, the most frequently reported nondental treatment-emergent adverse events were headache, infection, flu syndrome, and pain.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Click here for full Prescribing Information.

INDICATIONS

ARESTIN® (minocycline HCl) Microspheres, 1mg is indicated as an adjunct to scaling and root planning (SRP) procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN® may be used as part of a periodontal maintenance program, which includes good oral hygiene and SRP.

IMPORTANT SAFETY INFORMATION

  • ARESTIN is contraindicated in any patient who has a known sensitivity to minocycline or tetracyclines. Hypersensitivity reactions and hypersensitivity syndrome that included, but were not limited to anaphylaxis, anaphylactoid reaction, angioneurotic edema, urticaria, rash, eosinophilia, and one or more of the following: hepatitis, pneumonitis, nephritis, myocarditis, and pericarditis may be present. Swelling of the face, pruritus, fever and lymphadenopathy have been reported with the use of ARESTIN. Some of these reactions were serious. Post-marketing cases of anaphylaxis and serious skin reactions such as Stevens Johnson syndrome and erythema multiforme have been reported with oral minocycline, as well as acute photosensitivity reactions.